The New York Times -- Talks between the French pharmaceutical giant Sanofi-Aventis and the American biotech company Genzyme have hit a snag as the two sides seek to agree on a threshhold price that would allow Sanofi to proceed with due diligence, The Wall Street Journal reports.
